Search
Zongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigationalZongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDeuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigationalDeuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the dur...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSunvozertinib
go.drugbank.com/drugs/DB18925InvestigationalSunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCL...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for t...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Developed to circumvent the adherence barriers and strict administration requirements of peptide-based GLP-1 therapies, its small-molecu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesElzasonan
go.drugbank.com/drugs/DB18969InvestigationalElzasonan is under investigation in clinical trial NCT00275197 (A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesSevasemten
go.drugbank.com/drugs/DB18983InvestigationalSevasemten is under investigation in clinical trial NCT05291091 (Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone . It targets aldosterone excess, a primary underlying driver of tr...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOSU-6162
go.drugbank.com/drugs/DB19178InvestigationalOSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsMethylone
go.drugbank.com/drugs/DB19192InvestigationalMethylone is under investigation in clinical trial NCT05741710 (A Study to Assess the use of Methylone in the Treatment of PTSD).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates